Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 165


Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI.

Rasul S, Geist BK, Brath H, Baltzer P, Sundar LKS, Pichler V, Mitterhauser M, Kautzky-Willer A, Hacker M.

BMJ Open Diabetes Res Care. 2020 Mar;8(1). pii: e001135. doi: 10.1136/bmjdrc-2019-001135.


Utility of Absolute Quantification in Non-lesional Extratemporal Lobe Epilepsy Using FDG PET/MR Imaging.

Traub-Weidinger T, Muzik O, Sundar LKS, Aull-Watschinger S, Beyer T, Hacker M, Hahn A, Kasprian G, Klebermass EM, Lanzenberger R, Mitterhauser M, Pilz M, Rausch I, Rischka L, Wadsak W, Pataraia E.

Front Neurol. 2020 Jan 31;11:54. doi: 10.3389/fneur.2020.00054. eCollection 2020.


On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study.

Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M.

Transl Psychiatry. 2020 Jan 8;10(1):2. doi: 10.1038/s41398-019-0681-5.


Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data.

Unterholzner J, Gryglewski G, Philippe C, Seiger R, Pichler V, Godbersen GM, Berroterán-Infante N, Murgaš M, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R.

Cereb Cortex. 2020 Jan 28. pii: bhz341. doi: 10.1093/cercor/bhz341. [Epub ahead of print]


Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI.

Rischka L, Gryglewski G, Berroterán-Infante N, Rausch I, James GM, Klöbl M, Sigurdardottir H, Hartenbach M, Hahn A, Wadsak W, Mitterhauser M, Beyer T, Kasper S, Prayer D, Hacker M, Lanzenberger R.

Front Physiol. 2019 Nov 22;10:1422. doi: 10.3389/fphys.2019.01422. eCollection 2019.


Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.

Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR.

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):713-720. doi: 10.1007/s00259-019-04584-1. Epub 2019 Nov 28.


Toward the Optimization of (+)-[11C]PHNO Synthesis: Time Reduction and Process Validation.

Pfaff S, Philippe C, Nics L, Berroterán-Infante N, Pallitsch K, Rami-Mark C, Weidenauer A, Sauerzopf U, Willeit M, Mitterhauser M, Hacker M, Wadsak W, Pichler V.

Contrast Media Mol Imaging. 2019 Sep 30;2019:4292596. doi: 10.1155/2019/4292596. eCollection 2019.


Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M.

Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15.


Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET.

Kraus C, Hahn A, Sigurdardottir H, Spurny B, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R.

Brain Imaging Behav. 2019 Oct 10. doi: 10.1007/s11682-019-00195-4. [Epub ahead of print]


Correction: Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression.

Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R.

Transl Psychiatry. 2019 Oct 4;9(1):246. doi: 10.1038/s41398-019-0583-6.


Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR.

Silberbauer LR, Gryglewski G, Berroterán-Infante N, Rischka L, Vanicek T, Pichler V, Hienert M, Kautzky A, Philippe C, Godbersen GM, Vraka C, James GM, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Hahn A, Lanzenberger R.

Front Mol Neurosci. 2019 Jul 12;12:172. doi: 10.3389/fnmol.2019.00172. eCollection 2019.


Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI.

Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME.

Theranostics. 2019 May 27;9(12):3653-3658. doi: 10.7150/thno.31032. eCollection 2019.


Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.

Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29.


In vitro Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes.

Balber T, Benčurová K, Kiefer FW, Kulterer OC, Klebermass EM, Egger G, Tran L, Wagner KH, Viernstein H, Pallitsch K, Spreitzer H, Hacker M, Wadsak W, Mitterhauser M, Philippe C.

Front Endocrinol (Lausanne). 2019 Jun 11;10:324. doi: 10.3389/fendo.2019.00324. eCollection 2019.


(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging.

Berroterán-Infante N, Kalina T, Fetty L, Janisch V, Velasco R, Vraka C, Hacker M, Haug AR, Pallitsch K, Wadsak W, Mitterhauser M.

Eur J Med Chem. 2019 Aug 15;176:410-418. doi: 10.1016/j.ejmech.2019.05.008. Epub 2019 May 10.


Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941.

Vraka C, Pichler V, Pfaff S, Balber T, Hacker M, Mitterhauser M, Wadsak W, Philippe C.

J Vis Exp. 2019 Apr 28;(146). doi: 10.3791/59557.


Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging.

Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R.

Eur Neuropsychopharmacol. 2019 Jun;29(6):711-719. doi: 10.1016/j.euroneuro.2019.04.001. Epub 2019 May 8.


Multimodal [18 F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice.

Hayer S, Zeilinger M, Weiss V, Dumanic M, Seibt M, Niederreiter B, Shvets T, Pichler F, Wadsak W, Podesser BK, Helbich TH, Hacker M, Smolen JS, Redlich K, Mitterhauser M.

J Bone Miner Res. 2019 Sep;34(9):1632-1645. doi: 10.1002/jbmr.3748. Epub 2019 Jul 30.


Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using 18F-FDG-PET/CT and 18F-NaF-PET/CT.

Nakuz TS, Millinger FP, El-Rabadi K, Weber M, Pichler V, Wadsak W, Mitterhauser M, Haug A, Hacker M, Karanikas G, Pietschmann P, Agis H.

Anticancer Res. 2019 Apr;39(4):1943-1952. doi: 10.21873/anticanres.13304.


Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography.

Kalina T, Berroterán-Infante N, Schmitl S, Vraka C, Hacker M, Mitterhauser M, Pallitsch K, Wadsak W.

Future Med Chem. 2019 Mar;11(6):539-550. doi: 10.4155/fmc-2018-0444. Epub 2019 Mar 19.


Supplemental Content

Loading ...
Support Center